Skip to content

Released May 9, 2024, after the close

10-Q filed May 9, 2024, 39 days after period end · 0000950170-24-057213

Q1 2024 · 10-Q
Revenue$45.54M+81.3% vs Q1 2023+61.6% vs Q4 2023
Net Income-$32.16MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.27N/M vs Q1 2023no prior Q4 2023 on file
Gross Profit$24,188,000+97.0%
Operating Income-$60,182,000N/M
Operating Cash Flow-$62,476,000N/M
Free Cash Flowderived-$63,257,000N/M
Margins · derived
Gross margin53.1%+4.2 pt vs Q1 2023
Operating margin-132.2%−66.1 pt vs Q1 2023
Net margin-70.6%−3.6 pt vs Q1 2023

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$45.54M$25.12M$26.50M$32.79M
Net Income-$32.16M-$16.84M-$76.29M-$18.82M
EPS Diluted-$0.27-$0.21-$0.99-$0.25

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR